Research evaluated whether initiating breast cancer screening at age 30 may be preferable to current guidelines among survivors of childhood cancer with a history of chest irradiation.
The results of the first randomized clinical trial evaluating the link between a low-fat diet and breast cancer incidence and mortality were presented at ASCO 2019.
Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for Prostate Cancer
A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for metastatic castration-resistant prostate cancer.
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.
Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia.
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib.
The addition of pemetrexed to bevacizumab maintenance therapy after induction therapy for chemo-naive patients with advanced lung cancer did not meet the primary endpoint in a phase III trial.
Researchers tested the addition of a pemetrexed-carboplatin chemotherapy regimen to gefitinib for patients with EGFR-mutant advanced non–small-cell lung cancer.
A retrospective study finds that use of checkpoint inhibitors is associated with similar survival outcomes among patients with advanced non–small-cell lung cancer, regardless of a history of autoimmune disorders.